Medicure Inc.

Medicure Inc.

April 03, 2006 09:15 ET

Medicure To Present At BIO 2006

WINNIPEG, MANITOBA--(CCNMatthews - April 3, 2006) - Medicure Inc. (TSX:MPH)(AMEX:MCU), a cardiovascular drug discovery and development company, today announced it has been invited to make a corporate presentation at the Business Forum of BIO 2006. The Biotechnology Industry Organization's (BIO) Annual International Convention takes place from April 9-12, 2006 in Chicago, Illinois.

The BIO Business Forum runs simultaneously with the Annual International Convention, and provides a forum for growing biotechnology companies to meet with leaders in the investment, biotechnology, and pharmaceutical industries. Medicure's President and CEO, Albert D Friesen, PhD, will deliver the Company's corporate presentation at 9:00 am CST on April 12th, in Room B on Level 3 of McCormick Place South.

About Medicure Inc.

Medicure Inc. is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine, the largest pharmaceutical market sector. The Company's solid position in this field is supported by the following attributes:

- Cardiovascular focused pipeline: a global market of over US $70 billion

- Two drugs - MC-1 & MC-4232 - in late stage clinical development

- Four positive Phase II trials completed

- FDA Fast Track designation for MC-1

- Unique products addressing major, inadequately served markets

- Dual action antithrombotic, MC-45308, with positive preclinical results

Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule anti-ischemics and antithrombotics towards human clinical studies.

This press release contains forward-looking statements that involve risks, which may cause actual results to differ materially from the statements made, and accordingly may be deemed to be forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact Information

  • Medicure Inc.
    Derek Reimer
    Chief Financial Officer
    (888) 435-2220
    (204) 488-9823 (FAX)
    Medicure Inc.
    Hogan Mullally
    Manager of Investor & Public Relations
    (888) 435-2220
    (204) 488-9823 (FAX)